S&P 500   4,026.35 (+1.39%)
DOW   32,702.34 (+0.95%)
QQQ   313.07 (+1.94%)
AAPL   160.91 (+2.07%)
MSFT   280.61 (+1.95%)
META   205.50 (+2.40%)
GOOGL   101.42 (+0.39%)
AMZN   100.26 (+3.11%)
TSLA   193.40 (+2.23%)
NVDA   270.16 (+2.29%)
NIO   9.83 (+6.85%)
BABA   100.23 (+1.86%)
AMD   96.41 (+1.96%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   64.07 (+8.08%)
CGC   1.83 (+0.83%)
GE   94.09 (+1.02%)
DIS   96.75 (+2.04%)
AMC   4.99 (-3.11%)
PFE   40.21 (+0.55%)
PYPL   74.21 (+2.08%)
NFLX   331.35 (+2.42%)
S&P 500   4,026.35 (+1.39%)
DOW   32,702.34 (+0.95%)
QQQ   313.07 (+1.94%)
AAPL   160.91 (+2.07%)
MSFT   280.61 (+1.95%)
META   205.50 (+2.40%)
GOOGL   101.42 (+0.39%)
AMZN   100.26 (+3.11%)
TSLA   193.40 (+2.23%)
NVDA   270.16 (+2.29%)
NIO   9.83 (+6.85%)
BABA   100.23 (+1.86%)
AMD   96.41 (+1.96%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   64.07 (+8.08%)
CGC   1.83 (+0.83%)
GE   94.09 (+1.02%)
DIS   96.75 (+2.04%)
AMC   4.99 (-3.11%)
PFE   40.21 (+0.55%)
PYPL   74.21 (+2.08%)
NFLX   331.35 (+2.42%)
S&P 500   4,026.35 (+1.39%)
DOW   32,702.34 (+0.95%)
QQQ   313.07 (+1.94%)
AAPL   160.91 (+2.07%)
MSFT   280.61 (+1.95%)
META   205.50 (+2.40%)
GOOGL   101.42 (+0.39%)
AMZN   100.26 (+3.11%)
TSLA   193.40 (+2.23%)
NVDA   270.16 (+2.29%)
NIO   9.83 (+6.85%)
BABA   100.23 (+1.86%)
AMD   96.41 (+1.96%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   64.07 (+8.08%)
CGC   1.83 (+0.83%)
GE   94.09 (+1.02%)
DIS   96.75 (+2.04%)
AMC   4.99 (-3.11%)
PFE   40.21 (+0.55%)
PYPL   74.21 (+2.08%)
NFLX   331.35 (+2.42%)
S&P 500   4,026.35 (+1.39%)
DOW   32,702.34 (+0.95%)
QQQ   313.07 (+1.94%)
AAPL   160.91 (+2.07%)
MSFT   280.61 (+1.95%)
META   205.50 (+2.40%)
GOOGL   101.42 (+0.39%)
AMZN   100.26 (+3.11%)
TSLA   193.40 (+2.23%)
NVDA   270.16 (+2.29%)
NIO   9.83 (+6.85%)
BABA   100.23 (+1.86%)
AMD   96.41 (+1.96%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   64.07 (+8.08%)
CGC   1.83 (+0.83%)
GE   94.09 (+1.02%)
DIS   96.75 (+2.04%)
AMC   4.99 (-3.11%)
PFE   40.21 (+0.55%)
PYPL   74.21 (+2.08%)
NFLX   331.35 (+2.42%)
NASDAQ:PBYI

Puma Biotechnology - PBYI Stock Forecast, Price & News

$2.56
+0.10 (+4.07%)
(As of 03/29/2023 03:46 PM ET)
Add
Compare
Today's Range
$2.42
$2.61
50-Day Range
$2.21
$4.76
52-Week Range
$1.60
$5.16
Volume
217,881 shs
Average Volume
337,457 shs
Market Capitalization
$119.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Puma Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
213.7% Upside
$8.00 Price Target
Short Interest
Healthy
3.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Puma Biotechnology in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$172,216 Sold Last Quarter
Proj. Earnings Growth
100.00%
From $0.19 to $0.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

95th out of 999 stocks

Pharmaceutical Preparations Industry

31st out of 489 stocks


PBYI stock logo

About Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Stock News Headlines

Puma Biotechnology (NASDAQ:PBYI) Downgraded by StockNews.com
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
PBYI.OQ - | Stock Price & Latest News | Reuters
Puma Biotechnology, Inc. (PBYI)
Why Shares of Puma Biotechnology Rose This Week
15 Best Affordable Stocks Under $30
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
Short Volatility Alert: Puma Biotechnology, Inc.
H.C. Wainwright Keeps Their Buy Rating on Puma Biotechnology (PBYI)
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss
See More Headlines
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Company Calendar

Last Earnings
11/04/2021
Today
3/29/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PBYI
Employees
196
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+210.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$228 million
Cash Flow
$0.23 per share
Book Value
$0.47 per share

Miscellaneous

Free Float
36,753,000
Market Cap
$120.33 million
Optionable
Optionable
Beta
1.03

Key Executives

  • Alan H. AuerbachAlan H. Auerbach
    Chairman, President, CEO & Secretary
  • Maximo F. NouguesMaximo F. Nougues
    Chief Financial & Accounting Officer
  • Alvin F. Wong
    Chief Scientific Officer
  • Jeffrey Ludwig
    Chief Commercial Officer
  • Mariann Ohanesian
    Senior Director-Investor Relations













PBYI Stock - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings
or view top-rated stocks.

What is Puma Biotechnology's stock price forecast for 2023?

1 analysts have issued 1-year target prices for Puma Biotechnology's stock. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 210.1% from the stock's current price.
View analysts price targets for PBYI
or view top-rated stocks among Wall Street analysts.

How have PBYI shares performed in 2023?

Puma Biotechnology's stock was trading at $4.23 at the start of the year. Since then, PBYI stock has decreased by 39.0% and is now trading at $2.58.
View the best growth stocks for 2023 here
.

When is Puma Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our PBYI earnings forecast
.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.78. The biopharmaceutical company had revenue of $46.20 million for the quarter, compared to analyst estimates of $53.44 million. The firm's revenue was down 9.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.79) earnings per share.

What guidance has Puma Biotechnology issued on next quarter's earnings?

Puma Biotechnology issued an update on its first quarter 2023 earnings guidance on Thursday, March, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $47.00 million-$52.00 million, compared to the consensus revenue estimate of $51.00 million.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include Millennium Management LLC (5.87%), Renaissance Technologies LLC (3.72%), Globeflex Capital L P (1.23%), Morgan Stanley (1.09%), Rice Hall James & Associates LLC (0.84%) and Geode Capital Management LLC (0.83%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Michael Patrick Miller, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $2.58.

How much money does Puma Biotechnology make?

Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $120.33 million and generates $228 million in revenue each year.

How many employees does Puma Biotechnology have?

The company employs 196 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501.

This page (NASDAQ:PBYI) was last updated on 3/29/2023 by MarketBeat.com Staff